Quest Diagnostics Inc vs Lowe`s Companies Inc — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.48B), while Lowe`s Companies Inc trades at $188.88 (market cap $105.96B). The key difference: Lowe`s Companies Inc is far larger — about 4.2× Quest Diagnostics Inc's market cap, and Lowe`s Companies Inc pays the higher dividend (2.65%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Lowe`s Companies Inc for 98 Days on average.
| DGX | LOW | |
|---|---|---|
Market Cap | $25.48B | $105.96B |
Volume | 941,866 | 4,039,547 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $287.39 |
52-Week Low | $173.49 | $179.50 |
Typical Hold Time | 56 Days | 98 Days |
Enterprise Value | $31.23B | $144.81B |
Dividend Yield | 1.49% | 2.65% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
Lowe's (LOW) trades at $181.54, down 1.17% on the day, with a bearish technical signal and recent price weakness amid a slowing home improvement market. The company has beaten earnings estimates for the last three quarters, with a P/E of 15.96 and net income margin of 7.35%. Recent news highlights drone delivery tests with DoorDash and Alphabet, while cash flow improved in 2025 but is projected to decline in 2026.
The stock offers value with a consensus price target of $244.09, implying 34% upside, supported by a 60.79% buy rating from analysts. Risks include high debt levels, competitive pressure from Home Depot, and sensitivity to housing market trends. The current technical setup suggests near-term support at $179, with potential for a rebound if fundamentals hold.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →